Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial - Kalakonda, N; Maerevoet, M; Cavallo, F (Lancet Haematol, 2020)
et al.